论文部分内容阅读
钙通道阻滞剂(Calcium Channel Blockers,CCB)又称钙拮抗剂(CaLcium antagonist),自上个世纪七十年代CCB作为血管扩张药物应用以来,发展十分迅速,己成为治疗心、脑血管疾病的大家族。CCB类药物品种也己从第一代的三种原始型药物(维拉帕米、硝苯地平和地尔硫卓)扩展成种类繁多的60余种,并已发展到第三代。目前新的三通道CCB类药物贝尼地平(Benidpine)也已广泛应用于临床。动脉粥样硬化斑块的形成是一个多阶段的过程,内皮功能紊乱既是斑块形成的启始阶段,也存在于心血管病的整个
Calcium Channel Blockers (CCB), also known as CaLcium antagonist, has developed rapidly since the application of vasodilator drugs in the seventies of last century. It has become the treatment of cardiovascular and cerebrovascular diseases big family. The CCBs have also been expanded from the first generation of three primordial drugs (verapamil, nifedipine and diltiazem) into a wide variety of more than 60 species and have been developed to the third generation. Benidpine, the new three-channel CCB drug, has also been widely used clinically. Atherosclerotic plaque formation is a multi-stage process, endothelial dysfunction is not only the initial stage of plaque formation, but also in the whole cardiovascular disease